ATOPIC DERMATITIS

This study looked at whether tralokinumab could help adults with moderate-to-severe eczema who had not improved enough with dupilumab. Only 7 people took part before the study was stopped early. Participants received tralokinumab injections every two weeks for 24 weeks, and the m…

This study tested a drug called LY3454738 in 234 adults with moderate-to-severe atopic dermatitis (eczema). The goal was to see if it safely reduces skin redness, swelling, and itching. Participants received either the drug or a placebo for 52 weeks. The trial was stopped early, …

This study tested an experimental drug called IMG-007 in adults with moderate-to-severe atopic dermatitis (eczema). The main goal was to check if the drug is safe and to see how it works in the body. Only 13 people took part before the study was stopped early.

This study tested a prescription cream called ruxolitinib to see if it could improve sleep in adults with mild-to-moderate eczema who have trouble sleeping because of itching. About 47 people joined, but the study was stopped early. The cream was applied to affected skin, and sle…

This study tested an experimental drug called SAR444656 in 70 adults with moderate to severe eczema that wasn't controlled by creams or ointments. Participants received one of three doses of the drug or a placebo for 16 weeks. The goal was to see if the drug could reduce skin red…

This early-stage study tested a new drug called XmAb27564 in 23 people with plaque psoriasis or atopic dermatitis (eczema). The main goal was to see if the drug is safe and tolerable when given as multiple injections. The study was stopped early, so results are limited.

This study tested a probiotic mixture to treat atopic dermatitis (eczema) in children aged 0 to 3 years. Researchers measured changes in eczema severity and use of steroid creams over 12 weeks. The study was terminated early and only enrolled 4 participants, so no strong conclusi…

This study tested an experimental daily pill called RPT193 for adults with moderate-to-severe atopic dermatitis (eczema). The goal was to see if it could reduce skin redness, swelling, and itchiness over 16 weeks. The trial was terminated early, so results are limited. It involve…

This early-stage study tested a new drug called NM26-2198 in healthy people and adults with moderate-to-severe eczema (atopic dermatitis). The goal was to check safety and how the body processes the drug. The trial was stopped early, so results are limited.

This early-stage study aimed to test the safety of a new drug called LY3872386 in healthy volunteers and people with atopic dermatitis (eczema). The study was terminated early, so no meaningful results are available. Only 18 participants were planned, and the drug's effects on ec…

This early-stage study tested a new oral drug called IPG7236 in 63 healthy adults to see if it is safe and how the body processes it. The study was stopped early, so results are limited. It was designed to gather safety information for future research on atopic dermatitis (eczema…

This study aimed to understand how the drug tralokinumab affects the skin of people with moderate to severe atopic dermatitis (eczema). Researchers measured drug levels in skin samples and tracked clinical improvements. The goal was to learn which patients might benefit most from…

This study aimed to better understand the underlying causes of eczema (atopic dermatitis) by collecting data, blood, and skin samples from participants. It also compared two types of light therapy—broadband and narrowband UVB—to see which works better for moderate-to-severe eczem…

This study looked at babies under 6 months old with eczema to find out how they show discomfort, since they are too young to scratch or talk. Researchers filmed the babies and recorded their behaviors to better understand their itch and pain. The goal was to improve how doctors a…